证券日报网讯 1月7日，莱茵生物在互动平台回答投资者提问时表示，公司主要从事天然健康产品的生 产经营业务，专注于植物功能性成分的研发与生产，其中莽草酸产品是抗流感药物奥司他韦的生产原料 之一，目前该产品销量占公司营收比重较小。公司美国印州工厂聚焦天然甜味剂、部分功能性成分的生 产，目前海外业务生产经营正常。 （文章来源：证券日报） ...

Core Viewpoint - The control of Rhein Biotech (002166.SZ), known as the "first stock of plant extraction," will be transferred to Guangzhou Defu Nutrition, led by the well-known investment institution Defu Capital, alongside a strategic acquisition of 80% of Beijing Jinkangpu, a company specializing in food nutrition fortifiers [2][3]. Group 1: Company Overview - Rhein Biotech is a leading player in the global plant extraction industry, with over 20 years of experience in natural sweeteners, holding a significant market share in stevia and monk fruit extracts [3]. - The company has recently achieved a major milestone with its synthetic biology technology, which is expected to generate over 1 billion yuan in annual output once its first domestic production line reaches full capacity [3]. Group 2: Financial Performance - Despite revenue growth, Rhein Biotech's net profit attributable to shareholders decreased by 30.73% year-on-year in the third quarter of 2025, highlighting the industry's challenges of intensified competition and price pressure [3]. Group 3: Strategic Moves - The acquisition by Defu Capital is not merely a financial investment but aims to vertically integrate the industry chain by acquiring control and injecting assets to fill Rhein Biotech's downstream gaps [4]. - The injected asset, Beijing Jinkangpu, is a leader in the food nutrition fortifier sector, providing a strategic intent to create an industry closed loop, allowing Rhein Biotech's upstream natural extracts to supply high-value nutrition fortifiers and end products [4]. Group 4: Future Outlook - Post-acquisition, Rhein Biotech's development path is clear, with short-term synergies expected to enhance profitability and risk resilience [5]. - In the medium to long term, the company will transition from a single plant extract supplier to a comprehensive platform covering "natural raw materials—core ingredients—end formulations," expanding into broader health and nutrition sectors [5]. - The success of this integration will determine whether Rhein Biotech can navigate through cycles and secure a more significant position in the global health industry [5].

Core Viewpoint - The transfer of control and asset injection into Rhine Biotech is seen as a crucial move to address the company's operational challenges and enhance its market position following the departure of its founder due to regulatory penalties [1][2]. Group 1: Control Change and Asset Injection - Rhine Biotech's controlling shareholder, Qin Benjun, plans to transfer 8.09% of shares to Guangzhou Defu Nutrition for 645.6 million yuan, relinquishing 25.5% of voting rights [1][3]. - After the transfer, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as joint actual controllers [1][3]. - The company will also acquire an 80% stake in Beijing Jinkangpu Food Technology through a share issuance, marking a significant asset injection [1][5]. Group 2: Financial Performance and Challenges - For the first three quarters of 2025, Rhine Biotech reported revenues of 1.272 billion yuan, an increase of 8.73%, but a net profit of 70.4 million yuan, down 30.73% year-on-year [1][8]. - Qin Benjun faces significant financial pressure, with over 65% of his shares pledged and a financing balance of 207 million yuan due within six months [1][8]. Group 3: New Business Direction - The acquisition of Beijing Jinkangpu, a leader in food nutrition fortifiers, allows Rhine Biotech to enter the nutrition health sector, expanding its business model [7][10]. - Beijing Jinkangpu's revenue for 2023 to the first nine months of 2025 was 370 million yuan, 432 million yuan, and 338 million yuan, respectively [9]. - The transaction is expected to create a closed-loop industry chain from raw materials to formulation solutions, enhancing operational stability and risk resilience for Rhine Biotech [10]. Group 4: Market Reaction - Following the announcement of the control change and restructuring plan, Rhine Biotech's stock price hit the daily limit, closing at 9.57 yuan per share, a 10% increase [11].

Core Viewpoint - Rhine Biotech (002166) has officially disclosed its asset restructuring and control change plan after a 10-day trading suspension, intending to issue shares to Guangzhou Defu Nutrition Investment Partnership and change its controlling shareholder to Guangzhou Defu Nutrition [1][2] Group 1: Share Transfer and Control Change - The control change framework agreement was signed on December 22, where Qin Benjun, the controlling shareholder, will transfer 8.09% of shares to Guangzhou Defu Nutrition and relinquish 25.50% of voting rights while retaining 3% [2] - After the transaction, Guangzhou Defu Nutrition will hold 8.09% of shares and 11.17% of voting rights, while Qin Benjun will retain 28.50% of shares and 4.14% of voting rights [2] - The total transaction price is estimated at 646 million yuan, with a transfer price of 10.76 yuan per share, representing a premium of 23.68% compared to the closing price of 8.70 yuan before the suspension [2] Group 2: Strategic Intent and Business Expansion - Guangzhou Defu Nutrition, established on December 2, 2025, is an investment company focused on the healthcare sector, managing nearly 24 billion yuan in healthcare assets [3] - Rhine Biotech aims to leverage Defu Capital's resources to enhance its investment and acquisition capabilities in the healthcare sector, creating a comprehensive health ecosystem [3] - The company has signed agreements to acquire 80% of Beijing Jinkangpu, a leading enterprise in the field of nutritional fortifiers, thereby expanding its business into the nutritional fortifier formulation sector [4][6] Group 3: Financial Performance of Beijing Jinkangpu - As of September 2023, Beijing Jinkangpu reported total assets of 593 million yuan and net assets of 535 million yuan, with revenues of 338 million yuan and a net profit of 40.33 million yuan for the first three quarters of 2025 [4]

Core Viewpoint - The restructuring plan of Rhein Biotech (002166.SZ) involves a significant change in control, with the original controlling shareholder, Qin Benjun, transferring 8.09% of shares and relinquishing 25.5% of voting rights to introduce a new main shareholder, Guangzhou Defu Nutrition, while also acquiring 80% of Beijing Jinkangpu's equity to extend its business into the nutritional supplement sector [2][3][4]. Group 1: Shareholder Changes - Qin Benjun will transfer shares at a price of 10.76 CNY per share, totaling 645.6 million CNY, which is a premium of over 20% compared to the last closing price before suspension [2][4]. - Following the resumption of trading, Rhein Biotech's stock hit a daily limit up, reaching 9.57 CNY per share, marking a new high for the year and a market capitalization of 7.097 billion CNY [3]. - Qin Benjun's exit is attributed to financial pressures and operational difficulties faced by the company, including a recent penalty from the China Securities Regulatory Commission for market manipulation [5][6]. Group 2: Financial Performance and Challenges - Rhein Biotech's net profit from 2021 to 2024 showed significant volatility, with figures of 118 million CNY, 179 million CNY, 83 million CNY, and 163 million CNY, reflecting a concerning stability in profitability [7]. - In the first three quarters of 2025, the company reported revenue of 1.272 billion CNY, an increase of 8.73% year-on-year, but net profit decreased by 30.73% to 70.395 million CNY, indicating a tightening cash flow situation [9]. - As of September 2025, the company had only 255 million CNY in cash but faced short-term interest-bearing liabilities of 807 million CNY, highlighting liquidity issues [9]. Group 3: Strategic Acquisitions - The acquisition of 80% of Beijing Jinkangpu is part of a strategy to create a closed-loop supply chain from raw materials to formulation solutions in the nutritional supplement field [2][10]. - Beijing Jinkangpu reported a revenue of 432 million CNY and a net profit of 70.2658 million CNY in 2024, with a relatively stable financial condition, making it a strategic fit for Rhein Biotech [12]. - The acquisition is expected to enhance Rhein Biotech's product offerings in the dairy sector and leverage its global sales network for international expansion [15]. Group 4: Market Context and Future Prospects - The recent decision by the Ministry of Commerce to impose temporary anti-subsidy duties on EU dairy products may benefit domestic dairy producers, potentially creating a favorable environment for Rhein Biotech's new business direction [14]. - The U.S. federal government's recent reforms on cannabis regulation may open new opportunities for Rhein Biotech's industrial hemp business, particularly in CBD extraction [15][16]. - The establishment of Guangzhou Defu Nutrition, which is closely linked to the new controlling shareholders, indicates a strategic move to consolidate assets and enhance operational efficiency within the healthcare investment sector [13].

Core Viewpoint - The market reacted positively to the resumption of trading for Rhein Biotech, driven by announcements regarding a change in control and asset acquisition during the suspension period [1] Group 1: Control Change - Rhein Biotech's controlling shareholder, Qin Benjun, signed an agreement to transfer 60 million shares (8.09% of total shares) to Guangzhou Defu Nutrition at a price of 10.76 CNY/share, totaling 645.6 million CNY, representing a premium of 23.68% compared to the closing price of 8.70 CNY/share on December 9 [1] - Following the transfer, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Lizhenfu as the joint actual controllers of the company [1] Group 2: Asset Acquisition - Rhein Biotech signed agreements to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a share issuance [2] - The company will also issue shares to Guangzhou Defu Nutrition to raise funds for acquiring an additional 15.50% stake from individual shareholders Li Yang and Song Jun, with the issuance price set at 6.81 CNY/share [2] - This acquisition will expand Rhein Biotech's industry chain into the nutritional supplement sector, creating a closed-loop from raw materials to formulation solutions, enhancing business synergy and upgrading operations [2] Group 3: Financial Performance - Rhein Biotech's revenue for 2022, 2023, and 2024 is projected to be 1.4 billion CNY, 1.494 billion CNY, and 1.772 billion CNY, respectively, while net profit is expected to decline from 178 million CNY in 2022 to 82.51 million CNY in 2023 and 163 million CNY in 2024 [2] - In the third quarter of 2025, the company reported revenue of 1.272 billion CNY, an increase of 8.73% year-on-year, but net profit fell by 30.73% to 70.4 million CNY [2]

格隆汇12月17日丨莱茵生物(002166.SZ)在投资者互动平台表示，公司美国印州工厂于今年已升级改造 为综合提取工厂，但仍具备CBD的提取能力。 ...

Core Insights - The company reported significant profit growth in Q3 2025, with a net profit of 0.89 billion yuan, a year-on-year increase of 338.7% [1] - The company's revenue for the first three quarters of 2025 was 50.5 billion yuan, a decrease of 3.4% year-on-year, while the net profit reached 3.0 billion yuan, up 385.3% [1] Revenue and Profitability - In Q3 2025, the company achieved total revenue of 13.90 billion yuan, a decline of 19.9% year-on-year, but the net profit showed a substantial increase [1] - The gross profit margin for the plant extraction business was 20.86%, up 4.91 percentage points year-on-year, while the cottonseed business gross margin was 7.20%, an increase of 8.05 percentage points [1] - The company’s Q3 gross margin was approximately 16%, a significant increase of 10.6 percentage points year-on-year [2] Business Segment Performance - The plant extraction business generated revenue of 24.99 billion yuan in the first three quarters, a year-on-year increase of 7.35%, with a gross margin of 20.86% [1] - The cottonseed business reported revenue of 23.53 billion yuan, a decline of 10.54% year-on-year, but the gross margin improved to 7.20% [1] - Sales of various products in the plant extraction segment reached historical highs, with chili red pigment sales up 36% and chili essence sales up 87% year-on-year [1] Cost and Expense Management - In Q3, the company’s selling, administrative, and R&D expense ratios were 1.4%, 3.4%, and 3.4%, respectively, with increases in each category compared to the previous year [2] - The increase in selling expenses was primarily due to the recovery of the cottonseed business, leading to higher compensation for sales staff [2] Future Outlook - The company is positioned as a leader in the domestic plant extraction industry, with significant growth potential in both domestic and international markets [2] - Revenue projections for 2025-2027 are 70.1 billion yuan, 74.8 billion yuan, and 79.6 billion yuan, with net profits expected to be 3.74 billion yuan, 4.06 billion yuan, and 4.41 billion yuan, respectively [2]

证券日报网讯12月10日，莱茵生物（002166）在互动平台回答投资者提问时表示，公司植物提取产能充 足，目前备有一定的莽草酸存货，可随时响应市场需求。 ...

12月9日晚间，深耕植物提取领域25年的莱茵生物（002166.SZ）发布重磅公告，宣布筹划控制权变更及 资产收购事项，股票自12月10日起停牌。此次由管理超34亿美元基金的德福资本主导的资本运作， 以"控制权受让+优质资产注入"的模式，为这家全球植物提取领域标杆企业注入强劲发展动能。 作为天然健康原料领域的全球领军者，莱茵生物的技术硬实力为此次战略升级奠定坚实基础。公司不仅 手握300余项标准化植物成分提取技术，更搭建起"国家热带水果加工技术研发分中心"、"博士后科研工 作站"等多个国家级研发平台，其罗汉果甜苷全球市场份额稳定在20%-25%，甜叶菊提取物销量跻身全 球前三。在合成生物领域，公司已实现突破性进展，与江南大学合作完成罗汉果甜苷V全合成技术路 径，成为全球首家掌握该技术的企业，其甜菊糖苷RM2产品更是斩获美国FDA GRAS认证，正加速推动 天然健康甜味剂应用新浪潮。 双方的业务协同将构建强大产业闭环。莱茵生物的天然原料可直供金康普生产体系，解决终端产品的原 料品质保障问题；金康普的优质客户资源与国际渠道，则能为莱茵生物的高附加值产品开辟增量市场。 这种"上游原料供给+下游终端落地"的布局，将大 ...